Leading with purpose. Every day.
“Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.”
Emil D. Kakkis, M.D., Ph.D.
Chief Executive Officer and President
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercializationMeet our leadership team
We have one of the largest and most diverse pipelines in rare diseaseExplore our pipeline
Join our talented teamBrowse current opportunities
Latest newsView more news >
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
Ultragenyx Issues 2022 Environmental, Social and Governance (ESG) Report
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare diseaseRead our blog >